|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C16orf96 |
Gene summary for C16ORF96 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C16orf96 | Gene ID | 342346 |
| Gene name | chromosome 16 open reading frame 96 | |
| Gene Alias | C16orf96 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | A6NNT2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 342346 | C16orf96 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.20e-07 | 2.04e-01 | 0.3005 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C16orf96 | SNV | Missense_Mutation | novel | c.1628T>C | p.Val543Ala | p.V543A | A6NNT2 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A3KC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| C16orf96 | SNV | Missense_Mutation | novel | c.248N>C | p.His83Pro | p.H83P | A6NNT2 | protein_coding | deleterious(0) | benign(0.05) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| C16orf96 | SNV | Missense_Mutation | novel | c.3365N>T | p.Arg1122Ile | p.R1122I | A6NNT2 | protein_coding | deleterious(0) | probably_damaging(0.943) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| C16orf96 | SNV | Missense_Mutation | c.544G>T | p.Asp182Tyr | p.D182Y | A6NNT2 | protein_coding | deleterious(0) | possibly_damaging(0.73) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| C16orf96 | SNV | Missense_Mutation | novel | c.2721N>G | p.Phe907Leu | p.F907L | A6NNT2 | protein_coding | deleterious(0.05) | probably_damaging(0.996) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| C16orf96 | SNV | Missense_Mutation | c.1324C>G | p.Gln442Glu | p.Q442E | A6NNT2 | protein_coding | tolerated(0.24) | benign(0.01) | TCGA-XX-A899-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR | |
| C16orf96 | deletion | Frame_Shift_Del | c.1242delG | p.Pro415GlnfsTer42 | p.P415Qfs*42 | A6NNT2 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| C16orf96 | SNV | Missense_Mutation | novel | c.1408N>T | p.Arg470Trp | p.R470W | A6NNT2 | protein_coding | deleterious(0.01) | benign(0) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| C16orf96 | SNV | Missense_Mutation | c.274N>A | p.Glu92Lys | p.E92K | A6NNT2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-MU-A5YI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| C16orf96 | SNV | Missense_Mutation | c.2668N>C | p.Glu890Gln | p.E890Q | A6NNT2 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |